Zenas Biopharma

NSQ:ZBIO · US98937L1052

BiotechnologySmall

360

Medium confidence — indicative

Value—

Profit price17

Cash yield1

Sales & asset price37

Price/Sales50

Price/Book24

Quality38

Returns on capital20

Return on Capital32

Cash Return on Capital20

Return on Equity9

Profit margins17

Cash truth not applicable for financial companies.

Growth54

Sales growth85

Profit growth15

Reinvestment85

Price momentum65

Safety39

Debt load12

Debt serviceability18

Refinancing35

Debt Payback1

Liquidity54

Sentiment60

Analyst ratings45

Expectations trend59

Opinion Changes50

Price Target Upside68

Market mood35

Value Creation4/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Zenas Biopharma doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2019

Employees152

Websitezenasbio.com

ISINUS98937L1052

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

ImmunologyHematologyOphthalmologyRheumatologyNeurologyInflammationChronic DiseasesCentral Nervous SystemBiopharmaHealth CarePharmaceutical

Description

Zenas BioPharma, Inc. (‘Zenas’) operates as a clinical stage global biopharmaceutical company. The company is engaged in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving under…

Analysis

Middle-of-the-road

Zenas BioPharma, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 4/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Zenas Biopharma with its peers

Nkarta

NSQ:NKTX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Vera Therapeutics

NMQ:VERA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Kyverna Therapeutics

NSQ:KYTX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Corvus Pharmaceuticals

NMQ:CRVS

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

RAPT Therapeutics

NMQ:RAPT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Shattuck Labs

NSQ:STTK

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →